Clarity Capital Partners LLC Acquires New Position in Tempus AI, Inc. (NASDAQ:TEM)

Clarity Capital Partners LLC bought a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 48,536 shares of the company's stock, valued at approximately $2,341,000. Tempus AI accounts for approximately 0.9% of Clarity Capital Partners LLC's portfolio, making the stock its 21st biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Operose Advisors LLC bought a new position in Tempus AI in the 4th quarter worth $25,000. Cherry Tree Wealth Management LLC bought a new position in shares of Tempus AI during the 1st quarter valued at approximately $31,000. Farther Finance Advisors LLC purchased a new stake in Tempus AI in the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC raised its stake in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after acquiring an additional 965 shares during the period. Finally, Continuum Advisory LLC bought a new stake in Tempus AI during the 1st quarter worth approximately $39,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Tempus AI

In related news, CFO James William Rogers sold 23,121 shares of Tempus AI stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $63.27, for a total transaction of $1,462,865.67. Following the completion of the transaction, the chief financial officer directly owned 146,001 shares of the company's stock, valued at approximately $9,237,483.27. The trade was a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Theodore Leonsis sold 205,847 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $67.66, for a total transaction of $13,927,608.02. Following the completion of the sale, the director directly owned 15,511 shares of the company's stock, valued at approximately $1,049,474.26. The trade was a 92.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold 607,522 shares of company stock valued at $41,300,238 over the last three months. Corporate insiders own 27.60% of the company's stock.

Tempus AI Trading Up 2.5%

Shares of NASDAQ:TEM traded up $1.47 during trading on Friday, reaching $60.65. The company's stock had a trading volume of 6,389,112 shares, compared to its average volume of 7,393,926. The stock has a market capitalization of $10.50 billion and a PE ratio of -7.78. Tempus AI, Inc. has a 12 month low of $30.77 and a 12 month high of $91.45. The company has a current ratio of 1.71, a quick ratio of 1.56 and a debt-to-equity ratio of 2.45. The firm's 50 day simple moving average is $62.37 and its two-hundred day simple moving average is $53.83.

Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. The business had revenue of $255.74 million during the quarter, compared to analyst estimates of $248.13 million. Tempus AI had a negative return on equity of 533.21% and a negative net margin of 88.27%. The firm's revenue was up 75.4% compared to the same quarter last year. On average, research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Bank of America increased their price objective on shares of Tempus AI from $68.00 to $70.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 25th. Piper Sandler raised their price target on Tempus AI from $55.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, May 15th. BTIG Research initiated coverage on Tempus AI in a research note on Monday, April 21st. They issued a "buy" rating and a $60.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research report on Wednesday, May 7th. Finally, Guggenheim lifted their price target on shares of Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a report on Monday. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Tempus AI presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.67.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.